EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The T790M mutation is a primary cause of resistance to first- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).
• Third-generation EGFR TKIs, including AZD9291 (osimertinib), have been developed to overcome T790M-mediated resistance.
• However, acquired resistance to AZD9291 has emerged, with the C797S mutation identified as a significant resistance mechanism.

Purpose of the Study:

• To review the latest advancements in identifying the C797S resistance mutation in EGFR-mutated NSCLC.
• To discuss the development and potential of novel therapeutic strategies targeting C797S-mediated resistance.
• To highlight EAI045 as a selective inhibitor effective against C797S mutations.

Main Methods:

• Literature review of recent studies on EGFR mutations and TKI resistance.
• Analysis of data on the identification and clinical significance of the C797S mutation.
• Examination of preclinical and clinical data for novel inhibitors, specifically EAI045.

Main Results:

• The C797S mutation is a key mechanism conferring resistance to AZD9291 in EGFR-mutated NSCLC.
• EAI045 has demonstrated potent and selective activity against EGFR mutations, including those with the C797S mutation.
• EAI045 represents a promising therapeutic option for patients who have developed resistance to third-generation EGFR TKIs.

Conclusions:

• Targeting the C797S mutation is crucial for overcoming acquired resistance to advanced EGFR TKIs.
• EAI045 shows significant potential as a next-generation inhibitor for NSCLC patients with specific resistance mutations.
• Continued research into resistance mechanisms and novel inhibitors is essential for improving long-term patient outcomes.